Q1 Earnings Forecast for VRCA Issued By HC Wainwright

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Verrica Pharmaceuticals in a report issued on Wednesday, November 6th. HC Wainwright analyst O. Livnat expects that the company will post earnings of ($0.10) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Verrica Pharmaceuticals’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Verrica Pharmaceuticals’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.06) EPS and Q4 2025 earnings at ($0.06) EPS.

Other equities analysts have also issued reports about the stock. TD Cowen decreased their price objective on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday, October 21st. Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, November 5th. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Finally, Royal Bank of Canada downgraded Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $11.00 to $2.00 in a report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Verrica Pharmaceuticals has an average rating of “Hold” and an average target price of $9.60.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $0.96 on Monday. The company has a quick ratio of 2.23, a current ratio of 1.34 and a debt-to-equity ratio of 29.58. The stock has a market cap of $43.86 million, a P/E ratio of -0.53 and a beta of 1.45. The business’s 50 day moving average price is $1.55 and its 200-day moving average price is $5.00. Verrica Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The company had revenue of ($1.78) million during the quarter, compared to the consensus estimate of $7.53 million. Verrica Pharmaceuticals had a negative return on equity of 3,102.90% and a negative net margin of 625.06%.

Hedge Funds Weigh In On Verrica Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Quest Partners LLC purchased a new position in shares of Verrica Pharmaceuticals in the second quarter valued at $50,000. Key Financial Inc purchased a new position in shares of Verrica Pharmaceuticals in the 2nd quarter worth $69,000. Rhumbline Advisers increased its holdings in shares of Verrica Pharmaceuticals by 20.4% in the 2nd quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock worth $194,000 after buying an additional 4,514 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at about $332,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Verrica Pharmaceuticals by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after acquiring an additional 4,393 shares during the last quarter. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.